1. Home
  2. JAZZ vs CHH Comparison

JAZZ vs CHH Comparison

Compare JAZZ & CHH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAZZ
  • CHH
  • Stock Information
  • Founded
  • JAZZ 2003
  • CHH 1939
  • Country
  • JAZZ Ireland
  • CHH United States
  • Employees
  • JAZZ N/A
  • CHH N/A
  • Industry
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • CHH Hotels/Resorts
  • Sector
  • JAZZ Health Care
  • CHH Consumer Discretionary
  • Exchange
  • JAZZ Nasdaq
  • CHH Nasdaq
  • Market Cap
  • JAZZ 6.7B
  • CHH 5.7B
  • IPO Year
  • JAZZ 2007
  • CHH 1997
  • Fundamental
  • Price
  • JAZZ $110.27
  • CHH $134.36
  • Analyst Decision
  • JAZZ Strong Buy
  • CHH Hold
  • Analyst Count
  • JAZZ 12
  • CHH 14
  • Target Price
  • JAZZ $183.08
  • CHH $134.43
  • AVG Volume (30 Days)
  • JAZZ 651.1K
  • CHH 447.3K
  • Earning Date
  • JAZZ 07-30-2025
  • CHH 08-06-2025
  • Dividend Yield
  • JAZZ N/A
  • CHH 0.86%
  • EPS Growth
  • JAZZ 49.21
  • CHH 40.19
  • EPS
  • JAZZ 7.51
  • CHH 6.57
  • Revenue
  • JAZZ $4,064,808,000.00
  • CHH $797,663,000.00
  • Revenue This Year
  • JAZZ $6.05
  • CHH $103.49
  • Revenue Next Year
  • JAZZ $4.68
  • CHH $3.35
  • P/E Ratio
  • JAZZ $14.72
  • CHH $20.46
  • Revenue Growth
  • JAZZ 5.76
  • CHH N/A
  • 52 Week Low
  • JAZZ $95.49
  • CHH $116.20
  • 52 Week High
  • JAZZ $148.06
  • CHH $157.86
  • Technical
  • Relative Strength Index (RSI)
  • JAZZ 52.75
  • CHH 65.36
  • Support Level
  • JAZZ $109.27
  • CHH $130.42
  • Resistance Level
  • JAZZ $112.70
  • CHH $135.89
  • Average True Range (ATR)
  • JAZZ 2.72
  • CHH 2.63
  • MACD
  • JAZZ 0.42
  • CHH 0.84
  • Stochastic Oscillator
  • JAZZ 67.81
  • CHH 89.62

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

About CHH Choice Hotels International Inc.

As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.

Share on Social Networks: